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MaOBJECTIVES The aim of this meta-analysis was to compare the 30-day safety and efﬁcacy of bivalirudin with those of
heparin with or without routine administration of a glycoprotein IIb/IIIa inhibitor (GPI) in patients with acute coronary
syndrome (ACS).
BACKGROUND Bivalirudin has been a mainstay of anticoagulation in patients with ACS compared with heparin. The
extent to which trial results have been affected by the coadministration of heparin with a GPI, however, remains unclear.
METHODS A total of 13 randomized, controlled trials involving 24,605 patients were included.
RESULTS There was no signiﬁcant difference in 30-day mortality or myocardial infarction rate with bivalirudin
compared with heparin with or without routine GPI administration. A reduction of 30-day major bleeding was observed
with bivalirudin compared with heparin that was signiﬁcant when GPI was routinely administered (odds ratio [OR]: 0.52,
95% conﬁdence interval [CI]: 0.45 to 0.60), p < 0.001) but not with provisionally administered GPI (OR: 0.66, 95% CI:
0.33 to 1.32; p ¼ 0.24). The occurrence of stent thrombosis (ST) at 30 days was signiﬁcantly increased with bivalirudin
compared with heparin plus routinely administered GPI (OR: 1.67, 95% CI: 1.13 to 2.45, p ¼ 0.02), but not compared with
heparin plus provisionally administered GPI (OR: 2.08, 95% CI: 0.35 to 12.32, p ¼ 0.42). The rate of acute ST (#24 h),
however, was almost 4.5-fold higher with bivalirudin compared with heparin with or without GPI, whereas the rate of
subacute ST (24 h to 30 days) did not differ signiﬁcantly.
CONCLUSIONS Overall, bivalirudin in ACS patients is associated with a signiﬁcant reduction of major bleeding
compared with heparin plus routinely administered GPI, but with a marked increase in ST rates compared with heparin
with or without GPI. (J Am Coll Cardiol Intv 2015;8:201–13) © 2015 by the American College of Cardiology Foundation.m *Invasive Cardiology, National Research Council Institute of Clinical Physiology, Pisa, Italy; yDepartment of Internal Medicine,
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CI = conﬁdence interval
GPI = glycoprotein IIb/IIIa
inhibitor
IDR = ischemia-driven
revascularization
MI = myocardial infarction
NACE = net adverse clinical
event(s)
OR = odds ratio
PCI = percutaneous coronary
intervention
RCT = randomized, controlled
trial
ST = stent thrombosis
STEMI = ST-segment elevation
myocardial infarction
UFH = unfractionated heparin
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202A nticoagulation is a mainstay of treat-ment for patients with acute coro-nary syndrome (ACS) and is
recommended by international guidelines
(1,2). Intravenous heparin is traditionally
regarded as the standard anticoagulant strat-
egy to prevent ischemic events during the
early phase of ACS. Still, because of the large
intra- and interindividual variability and the
indirect mechanism of action of heparin
(3,4), alternative options have been devel-
oped. Bivalirudin, a short-acting intravenous
direct thrombin inhibitor, has shown supe-
rior safety compared with heparin plus
routinely or provisionally administered
intravenous glycoprotein IIb/IIIa inhibitor
(GPI) administration and has been regarded
as anticoagulant of choice in patients with
ACS. A recent randomized, controlled trial
(RCT) comparing bivalirudin with heparin
alone, however, found a signiﬁcant increasein the rate of myocardial infarction (MI) with bivalir-
udin and no difference in bleeding events (5), sug-
gesting that the diverging results among RCTs might
be inﬂuenced by the concomitant administration of
a GPI with heparin. The aim of this meta-analysis
was to compare the 30-day safety and efﬁcacy of biva-
lirudin alone with those of heparin combined with
either routinely or provisionally administered GPI in
ACS patients.METHODS
The presentmeta-analysis was performed according to
established methods recommended by the Cochrane
guidelines and in compliance with the PRISMA
(Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) statement for conducting sys-
tematic reviews and meta-analyses in health care
interventions (6,7).
STUDY DESIGN AND ENDPOINT SELECTION.
Selected endpoints were mortality, recurrent MI,
major bleeding, deﬁnite stent thrombosis (ST),
ischemia-driven revascularization (IDR), and net
adverse clinical events (NACE) within 30 days. NACE
were deﬁned as the composite of ischemia (which in
turn was deﬁned as the composite of death, MI,
repeat revascularization, along with ST and stroke),
and major bleeding. ST was deﬁned according to the
Academic Research Consortium criteria (8). Protocol-
deﬁned major bleeds were available across included
trials and used in the meta-analysis. Endpoint deﬁ-
nitions are detailed in Online Table 1.DATA SOURCE AND SEARCH STRATEGY. MEDLINE,
Cochrane Central Register of Controlled Trials,
Google Scholar, and Embase databases, as well
as www.tctmd.com, www.europcr.com, www.
clinicaltrials.gov, www.clinicaltrialresults.org, and
www.cardiosource.com websites were searched until
August 2014 for relevant studies. The following
key words were used: bivalirudin, acute coronary
syndrome, randomized controlled trial, ST-segment
elevation myocardial infarction (STEMI), non-ST-
segment elevation myocardial infarction. Relevant
citations were screened at the title/abstract level and
retrieved as full reports. Inclusion criteria were the
following: 1) human studies; 2) RCTs including further
analyses; 3) studies reporting clinical outcomes in
patients with ACS treated with bivalirudin compared
with heparin plus either routinely or provisionally
administered GPI; and 4) ACS data available from RCTs
conducted in mixed populations (stable coronary ar-
tery disease and ACS). Exclusion criteria were the
following: 1) nonrandomized registries; 2) elective
PCI or mixed populations studies without outcomes
reported in the ACS subset; 3) upstream administra-
tion by study design of another anticoagulant before
randomization.
DATA COLLECTION AND QUALITY ASSESSMENT.
Data were abstracted on pre-speciﬁed forms by 2 in-
dependent investigators not involved in any of the
retrieved studies. Internal validity was indepen-
dently appraised by 2 investigators; divergences were
resolved by discussion with a third investigator. The
potential risk of bias of RCTs was appraised by 2 un-
blinded investigators according to the Cochrane
Collaboration guidelines (concealment of treatment
allocation; blinding of participants, personnel, and
outcome assessors; adequate assessment of incom-
plete outcome data; selective outcome reporting;
other potential sources of bias) (7).
STATISTICAL ANALYSES. Data were analyzed ac-
cording to the intention-to-treat principle. Odds
ratios (ORs) and 95% conﬁdence intervals (CIs) were
used as summary statistics. Heterogeneity was
assessed by the Cochran’s Q test (9). Statistical het-
erogeneity was summarized by the I2 statistic, which
quantiﬁes the percent of variation in study results
that is due to heterogeneity rather than to chance (10).
Pooled ORs were calculated using the more con-
servative DerSimonian and Laird random-effects
model (7). Potential publication bias was examined
by constructing a funnel plot in which the SE of the
log OR was plotted against the OR of the selected
outcomes. Pre-speciﬁed sensitivity analyses were
performed in patients with STEMI and in those
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203treated with new P2Y12 receptor inhibitors. In case of
zero outcome events, continuity correction was per-
formed by adding a correction factor of 0.5 to the
number of events and nonevents in each intervention
group. The statistical level of signiﬁcance for the
summary treatment effect estimate was a 2-tailed
p value <0.05. Review Manager, version 5.1 (The
Nordic Cochrane Centre, Copenhagen, Denmark), and
SPSS version 15 (SPSS Inc., Chicago, Illinois), were
used for statistical computations.RESULTS
STUDY SELECTION AND PATIENT POPULATION.
A PRISMA ﬂow chart, describing the process of publi-
cation screening along with the reasons for exclusion,
is depicted in Online Figure 1. Of 652 potentially
relevant articles, 585 were excluded on the basis of
abstract content; 53 were further excluded during a
secondary screening as not meeting the inclusion
criteria; data from 13 studies and their analyses were
eventually abstracted (5,11–25) with a total of 24,605
patients included. Five studies enrolled all-comer
patient populations; thus only data regarding the
ACS subgroups were considered. More than 80% of the
included ACS patients underwent percutaneous cor-
onary intervention (PCI). In 11 studies, bivalirudin
was administered as an initial bolus of 0.75 mg/kg
followed by an infusion of 1.75 mg/kg/h for the dura-
tion of the procedure. The protocols of EUROMAX
(European Ambulance Acute Coronary Syndrome
Angiography) and TIMI-8 (Thrombolysis In Myocar-
dial Infarction-8) mandated prolonged infusions of
bivalirudin (until 4 h and 72 h, respectively). Because
in the EUROMAX trial, the use of GPI in the unfrac-
tionated heparin (UFH) arm was fairly high, w70%,
withw30% of heparin-treated patients compared with
88% of bivalirudin-treated patients who actually did
not receive GPI, the trial was included in the UFH þ
routinely administered GPI group. Data for overall and
stratiﬁed deﬁnite ST in the ACUITY (Acute Catheteri-
zation and Urgent Intervention Triage Strategy) trial
were available separately (12,13) and abstracted from
the respective populations of patients undergoing PCI
and quantitative coronary angiography analysis.
Online Table 2 lists the bias assessment for each RCT.
Online Figure 2 shows the funnel plots constructed for
each 30-day outcome, suggesting no publication bias
or small-study effect. Detailed characteristics of the
included studies are listed in Table 1.
30-DAY MORTALITY. Ten studies contributed to the
overall analysis of mortality, with 23,498 patients
included (Figure 1).Biva l i rud in versus hepar in with rout ine ly
admin istered GPI . The incidence of 30-day all-
cause death did not differ signiﬁcantly in the biva-
lirudin compared with the heparin plus routinely
administered GPI arm: 174 of 10,049 patients (1.73%)
receiving bivalirudin died compared with 182 of
10,360 patients receiving heparin plus GPI (1.76%)
(OR: 0.96, 95% CI: 0.77 to 1.20, p ¼ 0.71, heterogeneity
p ¼ 0.38, I2 ¼ 6%).
Biva l i rud in versus hepar in without rout ine ly
admin istered GPI . No signiﬁcant difference in
30-day mortality emerged between the 2 strategies:
66 of 1,911 patients (3.45%) receiving bivalirudin
compared with 58 of 1,913 patients (3.03%) receiving
heparin died (OR: 1.15, 95% CI: 0.80 to 1.64, p ¼ 0.46,
heterogeneity p ¼ 0.95, I2 ¼ 0%).
30-DAY MI. Eleven studies reported on the incidence
of 30-day MI among 23,521ACS patients (Figure 2).
Biva l i rud in versus hepar in with rout ine ly
admin istered GPI . In the bivalirudin arm, 476 of
10,056 patients (4.73%) had an MI compared with 460
of 10,376 patients (4.43%) in the heparin plus
routinely administered GPI arm (OR: 1.09, 95% CI:
0.95 to 1.24, p ¼ 0.22, heterogeneity p ¼ 0.71, I2 ¼ 0%).
Biva l i rud in versus hepar in without rout ine ly
admin istered GPI . There was no signiﬁcant differ-
ence in the 30-day rates of MI with bivalirudin
compared with heparin without routinely adminis-
tered GPI: 1.83% (35 of 1,911) in the bivalirudin group
and 1.09% (21 of 1,913) in the heparin group (OR: 1.44,
95% CI: 0.56 to 3.70, p ¼ 0.45, heterogeneity p ¼ 0.08,
I2 ¼ 60%).
30-DAY MAJOR BLEEDING. Protocol-deﬁned major
bleeding was reported in 12 RCTs involving a total
22,912 ACS patients (Figure 3).
Biva l i rud in versus hepar in with rout ine ly
admin istered GPI . The rate of protocol-deﬁned
major bleeding events was signiﬁcantly lower in the
bivalirudin (3.07% or 300 of 9,772) compared with the
heparin arm (5.74% or 563 of 9,803), resulting in a
48% OR reduction (OR: 0.52, 95% CI: 0.45 to 0.60,
p < 0.001, heterogeneity p ¼ 0.70, I2 ¼ 0%).
Biva l i rud in versus hepar in without rout ine ly
admin istered GPI . The magnitude of reduction of
protocol-deﬁned major bleeding was, however, not
signiﬁcant when bivalirudin was compared with
heparin without routinely administered GPI: 67 of
2,040 bivalirudin-treated patients (3.28%) compared
with 76 of 2,032 heparin-treated patients (3.74%)
experienced major bleeding (OR: 0.66, 95% CI: 0.33 to
1.32, p ¼ 0.24, heterogeneity p ¼ 0.03, I2 ¼ 62%).
30-DAY DEFINITE ST. Seven RCTs, involving 12,067
patients, reported a total of 147 events (Figure 4).
TABLE 1 Study Characteristics
Study (Ref. #) Year ACS Randomization ITT, n
Duration of
Bivalirudin Infusion
Bailout Use of
GP IIb/IIIa Inhibitor§ DES Use§
P2Y12 Use Before
Intervention§ P2Y12 Type Used
ACUITY (11–13) 2006 NSTEMI/UA Bivalirudin (bolus of 0.75 mg/kg followed
by infusion of 1.75 mg/kg/h)
4,612 Procedure duration;
continued at
physician’s discretion
238 (9.1) 1,547/2,597 (60)† 2,911 (64.2) Clopidogrel (63.9%)
Ticlopidine (0.7%)
UFH (bolus of 60 IU/kg þ infusion of
12 IU/kg/h) þGPI
4,603 NA 1,543/2,535 (61)† 2,842 (62.8) Clopidogrel (62.3%)
Ticlopidine (0.9%)
ARMYDA-BIVALVE (14),* 2012 NSTEMI/UA Bivalirudin (bolus of 0.75 mg/kg followed by
infusion of 1.75 mg/kg/h)
61 Procedure duration 24 (12)‡ 54 (27)‡ 61 (100) Clopidogrel (100%)
UFH (75 IU/kg body weight) 54 29 (14)‡ 58 (28)‡ 54 (100) Clopidogrel (100%)
BRAVE-4 (15) 2014 STEMI Bivalirudin (bolus of 0.75 mg/kg followed by
infusion of 1.75 mg/kg/h) þ prasugrel
271 Procedure duration 8 (3.0) 223 (82.3) 271 (100) Prasugrel (100%)
UFH (bolus of 70–100 IU/kg body weight) þ
clopidogrel
277 17 (6.1) 228 (82.3) 277 (100) Clopidogrel (100%)
BRIGHT (16) 2013/2014 STEMI/NSTEMI Bivalirudin (bolus of 0.75 mg/kg followed by
infusion of 1.75 mg/kg/h)
735 Procedure duration
(at least 30 min)
32 (4.4) NA 729 (100) Clopidogrel (100%)
UFH (bolus of 100 IU/kg body weight) 729 41 (5.7) NA 724 (99.9) Clopidogrel (99.9%)
UFH (bolus of 100 IU/kg body weight) þ
tiroﬁban
730 NA NA 723 (99.9) Clopidogrel (99.9%)
EUROMAX (17) 2013/2014 STEMI Bivalirudin (bolus of 0.75 mg/kg followed
by infusion of 1.75 mg/kg/h)
1,089 Procedure duration;
continued for 4 h
83 (7.9) 538 (57.1) 938 (86.1) Clopidogrel (50.0%)
Ticlopidine (0%)
Prasugrel (30.8%)
Ticagrelor (19.2%)
Heparin:
UFH (bolus of 100 IU/kg body weight)
UFH (bolus of 60 IU/kg body weight) þ GPI
LMWH (bolus of 0.5 mg/kg)
1,109 117 (25.4) 529 (55.9) 941 (84.9) Clopidogrel (51.5%)
Ticlopidine (0.2%)
Prasugrel (28.9%)
Ticagrelor (19.4%)
HEAT-PPCI (5) 2014 STEMI Bivalirudin (bolus of 0.75 mg/kg followed
by infusion of 1.75 mg/kg/h)
905 Procedure duration 124 (13.5) 730 (79.8) 911 (99.6) Clopidogrel (11.8%)
Prasugrel (27.3%)
Ticagrelor (61.2%)
UFH (70 IU/kg body weight) 907 142 (15.5) 730 (79.9) 909 (99.5) Clopidogrel (10.0%)
Prasugrel (27.6%)
Ticagrelor (62.7%)
HORIZONS-AMI (18) 2008 STEMI Bivalirudin (bolus of 0.75 mg/kg followed by
infusion of 1.75 mg/kg/h)
1,800 Procedure duration;
continued at
physician’s discretion
126 (7.5) NA 1,772 (98.7) Clopidogrel (95.7%)
Ticlopidine (0.4%)
UFH (bolus of 60 IU/kg body weight targeted
at ACT of 200–250 s) þ GPI
1,802 NA NA 1766 (98.2) Clopidogrel (95.1%)
Ticlopidine (0.4%)
ISAR-REACT 3 (19),* 2008 UA Bivalirudin (bolus of 0.75 mg/kg followed by
infusion of 1.75 mg/kg/h)
421 Procedure duration 4 (0.2)‡ 3,416 (88.3)‡ 421 (100) Clopidogrel (100%)
UFH (140 IU/kg body weight followed by
placebo infusion)
415 4 (0.2)‡ 3,383 (87.1)‡ 415 (100) Clopidogrel (100%)
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TABLE 1 Continued
Study (Ref. #) Year ACS Randomization ITT, n
Duration of
Bivalirudin Infusion
Bailout Use of
GP IIb/IIIa Inhibitor§ DES Use§
P2Y12 Use Before
Intervention§ P2Y12 Type Used
ISAR-REACT 4 (20) 2011 NSTEMI Bivalirudin (bolus of 0.75 mg/kg followed
by infusion of 1.75 mg/kg/h)
860 Procedure duration 0 (0) 757 (88) 860 (100) Clopidogrel (100%)
UFH (70 IU/kg body weight) þ abciximab 861 NA 764 (89) 861 (100) Clopidogrel (100%)
PROTECT-TIMI 30 (21) 2006 NSTEMI/UA Bivalirudin (bolus of 0.75 mg/kg followed
by infusion of 1.75 mg/kg/h)
284 Procedure duration;
continued for 4 h at
physician’s discretion
NA 677 (79) Clopidogrel (NA) Clopidogrel (NA)
Ticlopidine (NA)
Heparin:
UFH (bolus of 50 IU/kg body weight;
maximum of 5,000 U followed by
additional bolus targeted at ACT of
200–250 s) þ eptiﬁbatide
LMWH (bolus of 0.5 mg/kg) þ eptiﬁbatide
573 NA Clopidogrel (NA) Clopidogrel (NA)
Ticlopidine (NA)
Ray et al. (22) 2009 NSTEMI/STEMI Bivalirudin (bolus of 0.75 mg/kg followed
by infusion of 1.75 mg/kg/h)
7 Procedure duration 7 (77.7) NA 7 (100) Clopidogrel (100%)
UFH (bolus of 65 IU/kg body weight;
maximum 7,000 U, followed by additional
bolus targeted at ACT of >250 s) þ GPI
16 NA NA 16 (100) Clopidogrel (100%)
REPLACE-2* (23,24) 2004 UA Bivalirudin (bolus of 0.75 mg/kg followed by
infusion of 1.75 mg/kg/h)
669 Procedure duration 55 (8.2) NA 566 (84.6) Clopidogrel (84.6%)
UFH (bolus of 65 IU/kg body weight;
maximum of 7,000 U) þ GPI
682 NA NA 576 (84.4) Clopidogrel (84.4%)
TIMI-8 (25) 2002 NSTEMI/UA Bivalirudin (bolus of 0.1 mg/kg followed
by infusion of 0.25 mg/kg/h)
68 Procedure duration;
maintained for at least
72 h
0 (0) NA NA NA
UFH (bolus of 70 IU/kg plus infusion of
15 IU/kg/h targeted at aPTT of 55–85 s)
65 0 (0) NA NA NA
Values are n (%). *Only ACS patient data were retrieved for abstraction. †Data are shown for patients undergoing PCI. ‡Individual ACS patient-level data were unavailable and are presented as for the entire study population. §Procedure data.
ACS¼ acute coronary syndrome; ACT ¼ activated clotting time; aPTT¼ activated partial thromboplastin time; DES¼ drug-eluting stent; GPIIb/IIIa ¼ glycoprotein IIb/IIIa; ITT ¼ intention-to-treat; LMWH ¼ low molecular weight heparin; NA¼ not applicable; na¼ not
available; NSTEMI¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; PTCA ¼ percutaneous coronary angioplasty; P2Y12 ¼ purinergic receptor P2Y, G-protein coupled, 12; STEMI¼ ST-segment elevation myocardial infarction;
UA ¼ unstable angina; UFH ¼ unfractionated heparin; ACUITY ¼ Acute Catheterization and Urgent Intervention Triage Strategy trial; ARMYDA-7-BIVALVE ¼ Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty–Bivalirudin vs Heparin
Study; BRAVE-4 ¼ Bavarian Reperfusion Alternatives Evaluation 4 Trial; BRIGHT ¼ Bivalirudin versus Heparin Monotherapy and Glycoprotein IIb/IIIa Plus Heparin for Patients with AMI Undergoing Coronary Stenting; EUROMAX ¼ European Ambulance Acute Coronary
Syndrome Angiography; HEAT-PPCI ¼ How Effective are Antithrombotic Therapies in Primary PCI; HORIZONS-AMI ¼ Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial; ISAR-REACT 3 ¼ Intracoronary Stenting and
Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 3; ISAR-REACT 4 ¼ Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4; NA ¼ not available; PROTECT-TIMI 30 ¼ A Randomized Trial to Evaluate the
Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inﬂammation Among Antiplatelet and Antithrombotic Agents-Thrombolysis In Myocardial Infarction 30; REPLACE-2 ¼ Randomized Evaluation of PCI
Linking Angiomax to Reduced Clinical Events 2; TIMI-8 ¼ Thrombolysis in Myocardial Infarction 8 trial.
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FIGURE 1 Individual and Summary Odds Ratios With 95% CIs for the Outcome of 30-Day All-Cause Mortality in Acute Coronary Syndrome
Patients Treated With Bivalirudin Versus Heparin Stratiﬁed by Protocol Use of GP Inhibitors (Routine or No/Bailout Use)
ACUITY ¼ Acute Catheterization and Urgent Intervention Triage Strategy trial; BRAVE-4 ¼ Bavarian Reperfusion Alternatives Evaluation 4 Trial;
BRIGHT ¼ Bivalirudin Versus Heparin Monotherapy and Glycoprotein IIb/IIIa Plus Heparin for Patients With AMI Undergoing Coronary Stenting;
CI ¼ conﬁdence interval; EUROMAX ¼ European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial; HEAT-PPCI ¼ How Effective
Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention; GP ¼ glycoprotein; HORIZONS-AMI ¼ Harmonizing Outcomes
With Revascularization and Stents in Acute Myocardial Infarction; ISAR-REACT 4 ¼ Intracoronary Stenting and Antithrombotic Regimen: Rapid
Early Action for Coronary Treatment 4; M-H ¼ Mantel-Haenszel method; PROTECT-TIMI 30 ¼ A Randomized Trial to Evaluate the Relative
Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inﬂammation Among Antiplatelet and
Antithrombotic Agents-Thrombolysis In Myocardial Infarction 30; REPLACE-2 ¼ Randomized Evaluation of PCI Linking Angiomax to Reduced
Clinical Events 2.
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206The overall rate of 30-day deﬁnite ST increased sig-
niﬁcantly with bivalirudin compared with heparin
administration (1.59% vs. 0.84%), leading to an 86%
increase in the OR (OR: 1.86, 95% CI: 1.19 to 2.91, p ¼
0.006, heterogeneity p ¼ 0.22, I2 ¼ 27%) (Figure 4A).
Biva l i rud in versus hepar in with rout inely
admin is tered GPI . Bivalirudin treatment was asso-
ciated with a signiﬁcant 1.67-fold increase in ST (70 of
4,846 or 1.44%) compared with the heparin plus
routinely administered GPI arm (42 of 4,861 or 0.86%)
(OR: 1.67, 95% CI: 1.13 to 2.45, p ¼ 0.01, heterogeneity
p ¼ 0.56; I2 ¼ 0%) (Figure 4A).
Biva l i rud in versus hepar in without rout inely
admin is tered GPI . Bivalirudin was associated with a
numerically higher rate of ST (26 of 1,176 or 2.21%)
compared with heparin plus provisional use of a GPI
(9 of 1,184 or 0.76%), which, however, did not reach
statistical signiﬁcance (OR: 2.08, 95% CI: 0.35 to 12.32,
p ¼ 0.42, heterogeneity p ¼ 0.05, I2 ¼ 75%)
(Figure 4A).Tempora l pattern of deﬁn i te ST . Five RCTs pro-
vided data on the timing of ST: 4 involving 7,635
patients reported 66 (0.86%) acute ST events
(Figure 4B), and 4 (87 events in 9,852 patients or
0.88%) reported subacute ST (Figure 4C).
Acute ST (£24 h) . Bivalirudin treatment was asso-
ciated with a signiﬁcant almost 4.5-fold increase in
the OR of acute ST compared with heparin adminis-
tration: 54 of 3,801 patients in the bivalirudin arm
(1.42%) compared with 12 of 3,834 patients in the
heparin arm (0.31%) (OR: 4.49, 95% CI: 2.42 to 8.36,
p < 0.001, heterogeneity p ¼ 0.87, I2 ¼ 0%)
(Figure 4B). The magnitude and direction of the esti-
mates were consistent independent of the use of GPI
across the heparin arm (p < 0.001 and p ¼ 0.002 with
routine and provisional GPI use, respectively).
Subacute ST (>24 h to 30 days) . In contrast, there
was no signiﬁcant difference in the rate of subacute
ST between the 2 treatments in the overall analysis:
0.91% (45 of 4,922) in bivalirudin-treated patients
FIGURE 2 Individual and Summary Odds Ratios With 95% CIs for the Outcome of 30-Day Myocardial Infarction in Acute Coronary
Syndrome Patients Treated With Bivalirudin Versus Heparin Stratiﬁed by Protocol Use of GP Inhibitors (Routine or No/Bailout Use)
Abbreviations and study names as in Figure 1.
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207compared with 0.85% (42 of 4,930) in heparin-treated
patients (OR: 1.10, 95% CI: 0.62 to 1.97, p ¼ 0.74,
heterogeneity p ¼ 0.24; I2 ¼ 29%) (Figure 4C).
ISCHEMIA-DRIVEN REVASCULARIZATION. Ischemia-driven
revascularization (IDR) was reported by 8 studies
involving a total of 22,641 ACS patients (Online
Figure 3). In the overall analysis, bivalirudin was
associated with signiﬁcantly increased revascu-
larizations compared with heparin (OR: 1.32, 95%
CI: 1.01 to 1.71, p ¼ 0.04, heterogeneity p ¼ 0.19,
I2 ¼ 30%).
Biva l i rud in versus hepar in with rout inely
admin is tered GPI . There was a nonsigniﬁcant trend
toward increased rates of IDR with bivalirudin: 219 of
9,765 patients (2.24%) with bivalirudin compared
with 184 of 9,787 (1.88%) with heparin plus GPI
(OR: 1.20, 95% CI: 0.98 to 1.46, p ¼ 0.08, heteroge-
neity p ¼ 0.83, I2 ¼ 0%).
Biva l i rud in versus hepar in wi thout rout inely
admin is tered GPI . No signiﬁcant differences in IDR
were observed with bivalirudin as compared with
heparin (2.09% [40 of 1,911] vs. 1.30% [25 of 1,913],
respectively) (OR: 1.42, 95% CI: 0.47 to 4.30, p ¼ 0.54,
heterogeneity p ¼ 0.02, I2 ¼ 75%).
NET ADVERSE CLINICAL EVENTS. Net adverse clin-
ical events (NACE) deﬁned as the composite ofischemic events (death, MI, repeat revascularization,
along with ST and stroke) and major bleeding
were assessed in 9 RCTs involving 21,798 patients
(Figure 5).
Biva l i rud in versus hepar in with rout ine ly
admin istered GPI . There were signiﬁcantly fewer
NACE with bivalirudin compared with heparin plus
routinely administered GPI: 10.0% (977 of 9,765 pa-
tients) compared with 12.29% (1,203 of 9,787 patients)
(OR: 0.77, 95% CI: 0.65 to 0.91, p ¼ 0.002, heteroge-
neity p ¼ 0.01, I2 ¼ 65%).
Biva l i rud in versus hepar in without rout ine ly
admin istered GPI . Bivalirudin was associated with a
numerical but nonsigniﬁcant reduction in the OR of
NACE compared with heparin without routinely
administered GPI: 10.10% (151/1,495) compared with
12.85% (191/1,486), respectively (OR: 0.76, 95% CI:
0.51 to 1.13, p¼ 0.18, heterogeneity p ¼ 0.07, I2 ¼ 58%).
SENSITIVITY ANALYSES. STEMI subset . Bivalirudin
was associated with reduced rates of protocol-deﬁned
major bleeding compared with heparin plus routinely
administered GPI and increased rates of ST and MI
compared with heparin with or without routinely
administered GPI (Figure 6).
Novel P2Y12 inh ib i tors . In studies that allowed the
administration of prasugrel or ticagrelor, bivalirudin
FIGURE 3 Individual and Summary Odds Ratios With 95% CIs for the Day Protocol–Deﬁned Major Bleeding in Acute Coronary Syndrome
Patients Treated With Bivalirudin Versus Heparin Stratiﬁed by Protocol Use of GP Inhibitors (Routine or No/Bailout Use)
ARMYDA-7-BIVALVE ¼ Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty–Bivalirudin vs Heparin Study; other
abbreviations and study names as in Figure 1.
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208was associated with reduced rates of protocol-deﬁned
major bleeding compared with heparin plus routinely
administered GPI and increased rates of MI compared
with heparin with or without routine GPI use
(Figure 6).
Additional sensitivity analyses, performed by
removing each of the studies one at a time, demon-
strated that no single study inﬂuenced the overall
results.
DISCUSSION
The current meta-analysis is the largest in the ACS
setting to evaluate the 30-day safety and efﬁcacy of
bivalirudin compared with those of heparin in
conjunction with routine or provisional administra-
tion of a GPI. The main ﬁndings of this comprehen-
sive analysis are the following: 1) bivalirudin
treatment resulted in a signiﬁcant reduction of major
bleeding as compared with heparin with routinely
administered GPI but not with provisionally admin-
istered GPI; 2) bivalirudin compared with heparin was
associated with a signiﬁcant increase in 30-day deﬁ-
nite ST, largely driven by a greater than 4-foldincrease in acute (#24 h) ST regardless of routine or
provisional GPI use; 3) overall mortality or risk of MI
did not differ signiﬁcantly, but overall revasculari-
zation rates were signiﬁcantly increased with biva-
lirudin compared with heparin; and 4) consistently
with the overall analysis, the sensitivity analyses of
STEMI patients showed a reduction of major bleeding
compared with heparin plus GPI and increased ST
driving increased MI rates, with a reduction of major
bleeding compared with heparin with or without GPI.
Bivalirudin has been regarded in recent years as a
mainstay of anticoagulation in ACS patients under-
going coronary intervention, offering signiﬁcant
beneﬁts in terms of reduced bleeding events over
unfractionated or low molecular weight heparin.
Controversies have emerged, however, regarding
bivalirudin’s potential to prevent thrombotic com-
plications and its superior safety when compared
with heparin alone. In the ACUITY trial (11), no ben-
eﬁts were observed with bivalirudin in terms of death
and MI despite a signiﬁcant reduction in major
bleeding complications compared with heparin plus a
GPI. The HORIZONS-AMI trial, in which STEMI pa-
tients were randomized to bivalirudin or heparin plus
FIGURE 4 Individual and Summary Odds Ratios With 95% CIs for the Outcomes of 30-Day Deﬁnite Stent Thrombosis
(A) Stratiﬁed by protocol use of GPIs (routine or provisional use). Acute (B) and subacute (C) stent thrombosis in ACS patients treated with
bivalirudin versus heparin. *Deﬁnite or probable. GPI ¼ glycoprotein inhibitor; other abbreviations and study names as in Figure 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 , 2 0 1 5 Navarese et al.
J A N U A R Y 2 0 1 5 : 2 0 1 – 1 3 Bivalirudin Versus Heparin in Acute Coronary Syndrome
209GPI before primary PCI, the composite endpoint of
major adverse cardiovascular events (death, rein-
farction, target vessel revascularization, and stroke)
occurred at nearly identical rates by 30 days in the
2 treatment arms: 5.4% with bivalirudin versus 5.5%
with heparin plus a GPI. Yet, both major bleeding and
cardiovascular mortality were signiﬁcantly reducedin bivalirudin-treated patients, despite a signiﬁcant
increase in the risk of acute ST. Overall ST rates did
not differ in the 2 study groups at 30 days.
Consistent with the HORIZONS-AMI trial, the
recently published EUROMAX trial data (17) in pa-
tients with STEMI undergoing primary PCI showed
that bivalirudin, compared with heparin with or
FIGURE 5 Individual and Summary Odds Ratios With 95% CIs for the Outcome of 30-Day NACE Deﬁned as the Composite of
Ischemic Events (Death, Myocardial Infarction, Repeat Revascularization, Along With Stent Thrombosis and Stroke, If Available) and
Major Bleeding in ACS Patients Treated With Bivalirudin Versus Heparin Stratiﬁed by Protocol Use of GP Inhibitors (Routine or
Provisional Use)
NACE ¼ net adverse clinical event(s); other abbreviations and study names as in Figure 1.
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210without a GPI, signiﬁcantly reduced the incidence of
major bleeding, transfusions, and thrombocytopenia.
Yet, overall cardiovascular mortality did not differ
signiﬁcantly. Acute ST was signiﬁcantly higher with
bivalirudin regardless of prolonged infusions or the
use of novel P2Y12 inhibitors, whereas ST rates at 30
days did not differ signiﬁcantly between treatment
arms.
At variance with HORIZONS-AMI and EUROMAX,
the recently published HEAT-PPCI (How Effective are
Antithrombotic Therapies in Primary PCI) trial (5), a
single-center study comparing bivalirudin with hep-
arin alone in all-comers with STEMI, found bivalir-
udin to be associated with a numerical increase in
major bleeding and a signiﬁcantly higher rate of
major adverse cardiac events compared with heparin
alone. The excess of major adverse cardiac events
was mainly attributed to higher rates of MI in the
bivalirudin group. The 30-day rate of ST was also
signiﬁcantly increased with bivalirudin. Such differ-
ences in trial outcomes likely reﬂect the differences in
the use of GPI in the heparin arm. The present meta-
analysis in ACS patients clariﬁes on the largest
possible scale that the beneﬁt of bivalirudin inreducing major bleeding compared with heparin
depends on the concomitant GPI use, reaching sta-
tistical signiﬁcance only when bivalirudin is
compared with UFH plus routine but not provisional
GPI use.
An important ﬁnding of the current report is the
signiﬁcant 67% increase in the OR of ST at 30 days
with bivalirudin compared with heparin plus
routinely administered GPI. Moreover, ST increased
markedly with bivalirudin compared with heparin
with or without GPI in the very early phase, within
the ﬁrst 24 h, resulting in a greater than 4-fold
increased risk. On the other hand, the rates of sub-
acute ST (>24 h to 30 days) were comparable in the
bivalirudin and heparin arms. The analysis of overall
(30-day) deﬁnite ST showed a 186% signiﬁcant in-
crease in the bivalirudin arm, exclusively driven by a
higher incidence within the ﬁrst 24 h after PCI. Indi-
vidual reports had already demonstrated with biva-
lirudin treatment the propensity for ST to occur early
after coronary stenting in STEMI patients (26,27). This
is the ﬁrst meta-analysis to provide a comprehensive
time- and treatment-stratiﬁed analysis for ST in ACS
patients treated with bivalirudin or heparin with or
FIGURE 6 Sensitivity Analyses With Individual and Summary OR and 95% CIs for the 30-Day Clinical Outcomes Among STEMI Patients and in Trials That Included
the Use of Novel P2Y12 Inhibitors
na¼ not available; NACE¼ net adverse clinical event(s); ST¼ stent thrombosis; STEMI¼ ST-segment elevationmyocardial infarction; other abbreviations as in Figures 1 and 4.
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211without GPI in relation to the administered treat-
ment. The present ﬁndings are in agreement with
those of the HORIZONS-AMI trial that revealed an
increase in the rate of very early ST at 24 h with
bivalirudin monotherapy compared with heparin plus
GPI, which disappeared by 30 days and 1 year (28).
Taken together, the ﬁndings of this analysis sup-
port the paradigm concept that ischemic and bleeding
risks represent the extremes of a continuum in ACSpatients (29). Interestingly, both types of risk have
been found to increase mortality. The potential link
between bleeding complications and other adverse
outcomes including death can be explained not only
by hemorrhage-related blood loss and organ damage
but also—and equally importantly—by the discontin-
uation of antithrombotic therapies, the direct effect
of blood transfusions with stored red cells, and
the greater prevalence of comorbidities in patients
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212with bleeding. Thrombotic events may increase
mortality from coronary intervention by leading to
post-procedural (type 4) MI or stroke. The neutral
ﬁndings on mortality found in our analysis therefore
can be potentially explained by the opposite effect of
bivalirudin on major bleeding and thrombotic com-
plications—less major bleeding counterbalanced,
however, by a marked increase in the risk of stent-
related acute thrombotic events.
Among the different anticoagulant strategies
available for ACS patients (4,18), current guidelines
advocate the use of bivalirudin as the drug of choice
compared with heparin (1,2).
Coadministration of a GPI with heparin is aimed at
improving clinical outcomes of STEMI patients un-
dergoing primary PCI (30,31) and of selected high-
risk ACS patients with a high thrombus burden
(1,2). The present meta-analysis supports the safety
of bivalirudin in terms of reduced major bleeding
complications compared with heparin plus routinely
administered GPI, counterbalanced by a higher risk
of stent-related acute thrombotic events. The tran-
sient early increase in ST with bivalirudin might be
related to the pharmacokinetics of the drug and the
protocol of its administration. Bivalirudin is a
reversible direct thrombin inhibitor with a half-life of
w25 min; therefore, thrombin activity is restored
rapidly when the infusion stops. The propensity to-
ward acute ST may reﬂect a gap in antithrombotic
protection from the waning antithrombin effect of
bivalirudin on early discontinuation after interven-
tion and the delayed onset of platelet inhibition by
clopidogrel or the newer P2Y12 inhibitors (15).
Further studies are needed to deﬁnitively conﬁrm
or rule out the role of bivalirudin as an optimal
anticoagulant strategy for ACS patients and dif-
ferent bleeding-thrombotic risk proﬁles. The ongoing
MATRIX (Minimizing Adverse haemorrhagic events
by TRansradial access site and systemic Imple-
mentation of angioX) study, which incorporates 3randomized comparisons in a nonfactorial manner,
aims at conclusively ascertaining the role of bivalir-
udin infusion in the whole spectrum of ACS patients,
including clarifying the optimal duration of infusion
in patients undergoing PCI.
STUDY LIMITATIONS. The results of this meta-
analysis are derived from study-level data and not
from patient-level data. The ACS population included
the whole ACS spectrum and not only STEMI patients;
a separate analysis restricted to STEMI conﬁrmed the
results of the overall analysis. Furthermore, addi-
tional sensitivity analyses, performed by removing
each of the studies one at a time, demonstrated that
no single study inﬂuenced the overall results, sug-
gesting that the overall effect is robust and justiﬁed.
Different types of P2Y12 antagonists (clopidogrel,
prasugrel, ticagrelor) were used across and in trials;
this datum should be viewed as reﬂecting routine
real-world practice in all-comer ACS patients treated
with different antiplatelet drugs on the basis of
operator choice and drug availability; on the other
hand, the sensitivity analysis stratiﬁed by the use of
new P2Y12 antiplatelet agents conﬁrmed the ﬁndings
of the overall analysis, suggesting that the effect of
bivalirudin was not inﬂuenced by the use of these
new agents.
CONCLUSIONS
Overall, bivalirudin in ACS patients is associated with
a signiﬁcant reduction of major bleeding compared
with heparin plus routine GPI use, but with a marked
increase in the rates of acute ST compared with hep-
arin with or without GPI.
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